Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3849-3853

  Nikiteas, Nikolaos ^a   Yannopoulos, Athanasios ^a   Chatzitheofylaktou, Agapi ^a   Tsigris, Christos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adenocarcinoma; Colorectal cancer; DNA polymorphism; Interleukin 18; Oncogenesis

Indexed keywords

DNA; INTERLEUKIN 18;

ADENOCARCINOMA; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; ELECTROPHORESIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

ADENOCARCINOMA; ALLELES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; INTERLEUKIN-18; NEOPLASM STAGING; POLYMORPHISM, GENETIC;

EID: 37549051684     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108, 2005.
2. Ahmed FE: Gene-gene, gene-environment and multiple interactions in colorectal cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 24(1): 1-101, 2006.
3. Howell WM and Rose-Zerilli MJ: Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137: 194-199, 2007.
4. Kemp Z, Thirlwell C, Sieber O, Silver A and Tomlinson I: An update on the genetics of colorectal cancer. Hum Mol Genet 13(2): 177-185, 2004.
5. Wünsch Filho V and Zago MA: Modern cancer epidemiological research: genetic polymorphisms and environment. Rev Saude Publica 39(3): 490-497, 2005.
6. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G and Canzian F; Bellvitge Colorectal Cancer Study Group: Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63(13): 3560-3566, 2003.
7. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Wiltfang J, Avgoustidis D, Critselis E, Neukam FW and Patsouris E: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33(4): 504-507, 2007.
8. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris ACh, Patsouris E, Bramis J and Gazouli M: Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12(31): 5037-5043, 2006.
9. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R and Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15(6): 1126-1131, 2006.
10. Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, Raimondi C, Di Noto L, Bongiovanni A, Accardo A, Candore G, Palmeri L, Verna R, Caruso C, Lio D and Palmeri S: Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann NY Acad Sci 1089: 98-103, 2006.
11. Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellié C and Laurent-Puig P; members of the ANGH group: Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 6: 270, 2006.
12. Xu E, Lai M, Lu B, Xing X and Huang Q: No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese. Dis Colon Rectum 49(9): 1439-1444, 2006.
13. Vairaktaris E, Yapijakis C, Tsigris C, Vassiliou S, Derka S, Nkenke E, Spyridonidou S, Vylliotis A, Vorris E, Ragos V, Neukam FW and Patsouris E: Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer. Acta Oncol 46(8): 1097-1102, 2007.
14. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW and Patsouris E: Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21(4): 246-250, 2006.
15. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C and De Paoli P: Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55(1): 23-30, 2006.
16. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, Vylliotis A, Yapijakis C, Neukam FW and Patsouris E: A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 2007 PMID 17498910 (in press).
17. Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, Ragos V, Vylliotis A, Spyridonidou S, Tsigris C, Yannopoulos A, Tesseromatis C, Neukam FW and Patsouris E: Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res 27(1A): 459-464, 2007.
18. Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW and Patsouris E: Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17(4): 963-968, 2007.
19. Savage SA, Abnet CC, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR and Chanock SJ: Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13(12): 2251-2257, 2004.
20. Vairaktaris E, Yapijakis C, Kessler P, Vylliotis A, Ries J, Wiltfang J, Vassiliou S, Derka S and Neukam FW: Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132(4): 219-222, 2006.
21. Reszka E, Wasowicz W and Gromadzinska J: Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr 96(4): 609-619, 2006.
22. Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Derka S, Vasiliou S and Neukam FW: Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 25(3C): 2561-2565, 2005.
23. Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, Springer I, Nkenke E, Kessler P and Neukam FW: Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32(4): 455-457, 2006.
24. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P and Neukam FW: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42(9): 888-892, 2006.
25. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW and Patsouris E: The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol 82(11): 1010-1012, 2007.
26. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, Spyridonidou S, Vorris E, Neukam F and Patsouris E: The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133(10): 787-791, 2007.
27. Vairaktaris E, Yannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Critselis E, Avgoustidis D, Yapijakis C, Neukam FW and Patsouris E: Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 PMID 17428692 (In Press).
28. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y and Tedgui A: Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 88(5): 467-469, 2002.
29. Dinarello CA: Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27(1): 98-114, 2007.
30. Nilkaeo A and Bhuvanath S: Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediators of Inflammation 2006(3): 1-6, 2006.
31. Dinarello CA: Interleukin-18, a proinflammatory cytokine. Euro Cytok Netw 11(3): 483-486, 2000.
32. Akira S: The role of IL-18 in innate immunity. Curr Opin Immunol 12(1): 59-63, 2000.
33. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mizzanzanica D, Canevari S and Ferrini S: Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: Evidence for defective processing in tumor cells. In J Cancer 98: 873-878, 2002.
34. Nicolini A, Carpi A and Rossi G: Cytokines in breast cancer. Cytokine Growth Factor Rev 17: 325-337, 2006.
35. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH and Fridman WH: Modulation of interleukin-18 expression in human colon carcinoma: Consequences for tumor immune surveillance. Int J Cancer 84: 326-330, 1999.
36. Riedel F, Adam S, Feick P, Haas S Götte K and Hörmann K: Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 13(2): 267-272, 2004.
37. Diakowska D, Markocka-Maczka K, Grabowski K and Lewandowski A: Serum interleukin-12 and interleukin-18 levels in patients with esophageal squamous cell carcinoma. Exp Oncol 28(4): 319-322, 2006.
38. Ye ZB, Ma T, Li H, Jin XL and Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. -World J Gastroenterol 13(11): 1747-1751, 2007.
39. Wen Z, Ouyang Q, Chen D and Su X: Interleukin 18 expression in colon cancer and adenoma. Sichuan Da Xue Xue Bao Yi Xue Ban 34(2): 262-264, 2003.
40. Lebel-Binay S, Thiounn N, De Pinieux G, Viellefond A, Debré B, Bonnefoy JY, Fridman WH and Pagès F: IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer 106: 827-835, 2003.
41. Park H, Byun D, Kim TS, Kim YI, Kang JS, Hahm ES, Kim SH, Lee WJ, Song HK, Yoon DY, Kang CJ, Lee C, Houh D, Kim H, Cho B, Kim Y, Yang YH, Min KH and Cho DH: Enhanced IL-18 expression in common skin tumors. Immunology Letters 79: 215-219, 2001.
42. Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P and Kyriakou DS: Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leukemia Res 28: 259-266, 2004.
43. Giedraitis V, He B, Huang WX and Hillert J: Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112: 146-152, 2001.
44. Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z and Kinalska I: Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 51: 3347-3349, 2002.
45. Rueda B, González-Gay MA, Mataran L, López-Nevot and Martín J: Interleukin-18 promoter polymorphisms are not prevalent in rheumatoid arthritis. Tissue antigens 65: 544-548, 2005.
46. Zhang PA, Wu JM, Li Y and Yang XS: Relationship of interleukin-18 gene promoter polymorphisms with chronic hepatitis B in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22(5): 528-532, 2005.
47. Lee HM, Park SA, Chung SW, Woo JS, Chae SW, Lee SH, Kang HJ and Hwang SJ: Interleukin-18/-607 gene polymorphism in allergic rhinitis. Int J Pediatr Otorhinolaryngol 70: 1085-1088, 2006.
48. Vairaktaris E, Serefoglou Charalambus Z, Vassiliou S, Nkenke E, Yapijakis C, Chatzitheofylaktou A, Vylliotis A, Spyridonidou S, Neukam FW and Patsouris E: No association between the interleukin-18 -607 A/C gene polymorphism and risk for oral cancer. Anticancer Res 27(6): 4009-4012, 2007.
49. Golab J: Interleukin-18-interferon γ inducing factor-α novel player in tumor immunotherapy? Cytokine 12(4): 332-338, 2000.
50. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG and Li G: IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinase-9 (MMP-9) expression. Leukemia Res 28: 91-95, 2004.
51. Asakawa M, Kono H, Amemiya H, Matsuda M, Suzuki T, Maki A and Fujii H: Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 118: 564-570, 2006.
52. Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, Secondino S, Bucovec R and Gardani GS: Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents 14(4): 275-277, 2000.
53. Cao R, Farnebo J, Kurimoto M and Cao Y: Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB 13: 2195-2202, 1999.
54. Sivalingam SP, Yoon KH, Koh DR and Fong KY: Single-nucleotide polymorphisms of the interleukin-18 gene promoter region in rheumatoid arthritis patients: protective effect of AA genotype. Tissue Antigens 62: 498-504, 2003.
55. Boraschi D and Dinarello CA: IL-18 in autoimmunity: review. Eur Cytokine Netw 17: 224-252, 2006.